# Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster

> **NCT07099157** · PHASE4 · RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 140 (estimated)

## Conditions studied

- Herpes Zoster

## Interventions

- **DRUG:** Brivudine
- **DRUG:** Famciclovir

## Key facts

- **NCT ID:** NCT07099157
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-01-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07099157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07099157, "Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07099157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*